Wragge & Co LLP has boosted its life sciences practice with the appointment of a new regulatory specialist. Liz Fuller joins as director, life sciences regulatory (US qualified), bringing expertise in pharmaceutical and biotech regulatory affairs.

Liz is a US-qualified lawyer with more than 20 years' experience, including 15 years focusing on life sciences regulatory matters. She was previously general counsel at Triskel Integrated Services, a Geneva-based biotech development consultancy. Previous experience includes working with some of the leading names in the pharmaceutical and biotechnology industries in the EU and the US.

Patrick Duxbury, head of life sciences, said: "Liz's experience encompasses a wide range of regulatory issues concerning the development and regulation of pharmaceutical and biotechnology products. With a network of contacts across Europe, and significant knowledge of the sector, she represents a valuable addition to our regulatory capability."

Her expertise is primarily focused on regulatory issues surrounding biologics in the EU, particularly with biosimilars. Liz has also worked on successful applications of both hGH in the EU and US and erythropoietin products in the EU. In addition, she is experienced in technology licensing, contract drafting and negotiation, both in biotechnology and other pharmaceutical contexts.

Liz Fuller said: "I am excited to be part of a firm that boasts such a significant life sciences practice. Wragge & Co is highly regarded for its work in the pharmaceutical and biotech industries and has a wealth of experience in this specialist sector. I look forward to further developing my practice at the firm."

Wragge & Co has also appointed Dr Luke Kempton as partner. With significant expertise in life sciences litigation and transactions, Luke will be a major force in driving forward the life sciences practice.

The firm's 16-lawyer Life Sciences team delivers a unique mix of IP, corporate, antitrust, regulatory and dispute resolution advice to key players in the sector. The team also represents a number of life sciences clients in patent and regulatory litigation. The national practice is ranked among the leading teams in the sector by Chambers UK, praised for its "commercial oomph" and industry insight. Partners Patrick Duxbury and Dr Luke Kempton are highly regarded for their non-contentious work, with partner Huw Evans receiving plaudits for acting on contentious matters.

The team acts for a broad range of clients, from start-up to multinational, on a growing number of high-profile, cross-border collaborations and patent litigation cases. Notable clients include AstraZeneca, Astex Therapeutics, Genentech, the Medical Research Council, Prosidion, Inverness Medical Innovations, Chroma Therapeutics, MedImmune and 3i. Significant deals in the last year include a £200 million collaboration agreement with Silence Therapeutics to develop novel respiratory therapeutics.

---

For further information about this press release, contact Kathryn Hobbs on +44 (0)121 213 2397, Alexa Highfield on +44 (0)121 213 2396 or Matthew Purcell on +44 (0)121 213 2360

This press release may contain information of general interest about current legal issues, but does not give legal advice.